

MILLIPORE

Ki-67 Assay

(Mouse primary antibody)

For High Content Screening

For 5 x 96-well plates

Cat. No. HCS206

FOR RESEARCH USE ONLY
Not for use in diagnostic procedures.

USA & Canada

Phone: +1(800) 437-7500 • Fax: +1 (951) 676-9209 • Europe +44 (0) 23 8026 2233

Australia +61 3 9839 2000 • Germany +49-6192-207300 • ISO Registered worldwide
www.Millipore.com

Introduction

(i) High Content Screening and Drug Discovery

The development of High Content Screening (HCS) technology represents a major step towards improving the drug discovery and development process [1]. HCS enables the evaluation of multiple biochemical and morphological parameters in cellular systems and enables characterization of the subcellular distribution of fluorescent signals with labeled reagents. By combining the automated imaging of cells in microtiter plates with high-quality detection reagents and powerful image analysis algorithms, scientists can now acquire deeper knowledge of multiple morphological or biochemical pathways at the single-cell level, usually in a single assay, at an early stage in the development of new drugs. HCS platforms such as the IN Cell Analyzer (GE Healthcare), ArrayScan (ThermoFisher Scientific), or Opera (Perkin Elmer), can be used to deliver detailed profiles of cellular systemic responses [2].

(ii) Ki-67 as a marker of proliferation and its significance for Drug Discovery

The Ki-67 antigen (Ki-67) is a classic marker of cellular proliferation and has found widespread application in diagnostic, research and drug discovery applications [3, 4, 5]. The Ki-67 antigen was originally defined by the monoclonal antibody Ki-67, the name being derived from the city of origin (Kiel) and the number of the original clone in the 96-well plate [6]. Ki-67 antigen is preferentially expressed during late G1, S, G2 and M phase of the cell cycle, while resting, non-cycling cells (G0 phase) lack Ki-67 expression. Thus, Ki-67 is commonly used as a proliferation marker [3].

The proliferation index, defined as the percentage of proliferating cells in a population, is an important parameter in evaluation of the *in vitro* stimulation potency of growth factors and the antiproliferative activity of drugs [7], as well as being a sensitive marker of cytotoxicity [8, 9]. Signals that regulate cell proliferation represent potential targets for new cancer treatment strategies. Indeed, one of the most widely pursued strategies in drug discovery is the identification and characterization of therapeutic compounds able to inhibit cell proliferation [10-13]. Additionally, application of Ki-67 as a pharmacodynamic marker of the effectiveness of cancer therapy has been reported to hold great promise for rapid evaluation of new drugs [4]. High-Content Screening is now well-established as an ideal tool with which to characterize cellular proliferation [7-13].




Figure 1. Eukaryotic cell cycle marker expression and effects of cell cycle phase blocking agents.

Ki-67 is expressed throughout all phases of the cell cycle except G0. The protein exhibits punctate nuclear localization during the G1, S and G2 phases, then becomes homogeneously expressed throughout the nucleus during M phase. Compounds such as etoposide (a DNA topoisomerase II inhibitor) and paclitaxel (a microtubule stabilizer) are capable of arresting the cell cycle at S/G2 and G2/M phases, respectively.

Application

Millipore's HCS206 assay provides a complete solution for identifying and quantifying Ki-67 expression in cellular imaging applications. The reagents in the kit have been specifically optimized for HCS applications.

The assay is designed to enable quantification of the proliferation index, characterization of proliferating cells and classification of compounds that inhibit or induce cellular proliferation. The assay is also useful for *in vitro* toxicology applications. The nuclear dye (Hoechst 33342) may be used for measurements of cell number, DNA content and nuclear size. Additionally, the assay can be multiplexed with other probes for correlating cell proliferation with other biological markers e.g. for drug efficacy or toxicity.

The assay is immunofluorescence-based, and utilizes a high quality mouse monoclonal antibody which identifies Ki-67 with high sensitivity and specificity in human cells. Other species reactivity must be determined by the end user.

The superior Millipore reagents provided with this kit enable the user to reproducibly generate images with a high signal-to-background ratio, greatly facilitating HCS. In addition, working solutions of the primary and secondary antibodies are stable for at least 24 hours at room temperature (Figure 2), a great benefit for large-scale screening applications. The straightforward sample preparation and processing protocol takes less than 2.5 hrs after fixation.

Reagents are provided for 5 x 96-well microplates – *i.e.*, sufficient to perform 480 separate experiments. The kit includes a primary antibody for Ki-67, a Cy3-conjugated secondary antibody, Hoechst HCS Nuclear Stain, HCS Fixation Solution, HCS Immunofluorescence Buffer, HCS Wash Buffer, and Plate Sealers. Two control compounds, the chemotherapeutic drugs etoposide and paclitaxel, along with DMSO for Compound Serial Dilution and Compound Dilution Buffer, are also included in the kit, sufficient for duplicate 12-point dose response samples per plate (see Assay Procedure). Etoposide, a DNA topoisomerase II inhibitor, and paclitaxel, a microtubule stabilizer, have been demonstrated to induce mitotic block at S/G2 phase and G2/M phase, respectively [14, 15]. S/G2 phase block diminishes the proportion of cells reaching M phase (decreased homogeneous nuclear Ki-67), while G2/M phase block causes an accumulation of cells demonstrating characteristic M phase-Ki-67 expression (see Figure 1).

Kit Components

1. Mouse Anti-Ki-67 HCS Primary Antibody, 100X: (Part No. CS201642) 1 vial containing 300 μ L.
2. HCS Secondary Antibody (donkey anti-mouse IgG, Cy3 conjugate), 200X: (Part No. CS200437) 1 vial containing 150 μ L.
3. Hoechst HCS Nuclear Stain, 200X: (Part No. CS200438) 1 vial containing 150 μ L.
4. HCS Fixation Solution with Phenol Red, 2X: (Part No. CS200434) 1 bottle containing 100 mL.
5. HCS Immunofluorescence Buffer, 1X: (Part No. CS200435) 1 bottle containing 1000 mL.
6. HCS Wash Buffer, 1X: (Part No. 2007643) 1 bottle containing 500 mL.
7. Etoposide (S/G2 Arrest Control Compound), 250X: (Part No. CS200439) 1 vial containing 100 μ L.
8. Paclitaxel (G2/M Arrest Control Compound), 250X: (Part No. CS201655) 1 vial containing 100 μ L.
9. DMSO for Compound Serial Dilution: (Part No. CS200441) 1 bottle containing 10 mL.
10. Compound Dilution Buffer: (Part No. CS200442) 1 bottle containing 25 mL.
11. Plate Sealers: (Part No. CS200443) 10 each.

Materials Required But Not Provided

1. Sterile, tissue culture-treated black/clear bottom microplates suitable for High-Content Imaging.
2. Cell-type for assay, *e.g.*, HeLa (human cervical adenocarcinoma, ATCC #CCL-2) or A549 (human lung carcinoma, ATCC #CCL-185).
3. Tissue culture instruments/supplies (including 37°C incubator, growth media, flasks/plates, detachment buffer, etc.) for cell type of interest.
4. HCS imaging/analysis system, *e.g.*, GE Healthcare IN Cell Analyzer 1000 with Investigator software. System must be equipped with beam-splitters and filters capable of reading emission spectra in the blue and red ranges. Detailed image acquisition and analysis guidelines are provided in Table 2.

Warnings and Precautions

1. This product contains hazardous materials. Refer to MSDS for further information.

Component	Hazardous Constituent	Warnings (See MSDS)
HCS Fixation Solution	Formaldehyde	Toxic, carcinogen, combustible, readily absorbed through skin
Hoechst HCS Nuclear Stain	Hoechst 33342	Harmful, potential mutagen
Etoposide	Etoposide	Toxic
Paclitaxel	Paclitaxel	Harmful, potential mutagen
DMSO	Dimethyl sulfoxide	Combustible, readily absorbed through skin

2. For Research Use Only. Not for use in diagnostic procedures.

Stability and Storage

When stored under the conditions indicated on the labels, the kit components are stable up to the expiration date. HCS Fixation Solution, HCS Immunofluorescence Buffer, HCS Wash Buffer, DMSO, Compound Dilution Buffer, and Plate Sealers should be stored at 2-8°C. HCS Primary Antibody, HCS Secondary Antibody, Hoechst HCS Nuclear Stain, Etoposide and Paclitaxel should be stored at -20°C, avoiding repeated freeze/thaw cycles. (Note: If kit is expected to be used for multiple experiments, rather than a single use, thaw antibodies, nuclear stain and control compounds and dispense into appropriately sized aliquots. Store aliquots at -20°C.)

Discard any remaining reagents after the expiration date.

Assay Procedure

Note: The HCS206 assay protocol has been optimized for HeLa human cervical carcinoma (ATCC #CCL-2) and A549 human lung carcinoma (ATCC #CCL-185) cells. However, this kit is suitable for proliferation/cell cycle HCS analysis of a variety of human cell types. Alternate species reactivity must be confirmed by the end user.

Cell Preparation:

1. Prior to cell seeding for assay, culture HeLa or A549 cells in growth media until ~70-80% confluent.
2. Detach cells from culture flasks/plates via method appropriate for cell type of interest. Adjust cell density to $5-7 \times 10^4$ cells/mL in growth media. Add 90 μ L of this cell suspension (4500-6300 cells) to each well (for a 96-well plate, 4500-6300 cells/well is approximately equivalent to 15,000-21,000 cells/cm² of well surface). After adding cells to plate, allow plate to sit on a level surface at room temperature for 15-30 min, which allows for even cell distribution. Following this period, incubate cells in growth media (37°C/5% CO₂) for 48 hours.
3. Cell treatments (cell-cycle arrest control compounds, test compounds, etc.) can be introduced at any point during this culture period, as appropriate for time-course of treatment of interest. Etoposide (S/G2 arrest) and paclitaxel (G2/M arrest) are provided as cell-cycle arrest control compounds. Sufficient reagents are provided for duplicate 12-point dose response curves (including one DMSO-control set within the dose response) for all five 96-well plates. The compounds are provided at 250X concentration (assuming maximum treatments of 100 μ M and 1 μ M for etoposide and paclitaxel, respectively). Recommended treatment preparation involves half-log (1: $\sqrt{10}$) serial dilution of the 250X compound in DMSO, followed by dilution in Compound Dilution Buffer to 10X. 10 μ L of each treatment may then be added to the 90 μ L of culture media already present in each well, for a final 1X concentration (0.4% DMSO). Sample data is provided for 4 hours of compound treatment at 37°C prior to fixation.

Cell Fixation and Immunofluorescent Staining:

Note: Staining time is ~2.5 hours post-fixation. Do not allow wells to dry out between staining steps. Aspiration and dispensation of reagents should be conducted at low flow rates to diminish any cell loss due to fluid shear. All recommended 'per well' volumes refer to a single well of a 96-well microplate. All recommended 'per 96-well plate' volumes include 25% excess for liquid handling volume loss. All staining steps are

performed at room temperature (RT). All buffers and antibody solutions are stable for at least 24 hours at RT (see Figure 2).

4. At end of culture period, pre-warm HCS Fixation Solution (2X) to room temperature (RT) or 37°C if desired (12 mL/96-well plate). In a chemical fume hood, add 100 µL/well directly to culture media and allow to fix for 30 min at RT. Remove fixative/toxin-containing media and dispose of in compliance with regulations for hazardous waste (see MSDS). If proceeding immediately to staining, rinse each well twice with 200 µL of HCS Immunofluorescence Buffer. Alternatively, if plates are to be stained at a later time, rinse twice with 200 µL of Wash Buffer, then leave second rinse volume in wells and store plates tightly sealed at 4°C until staining.
5. If fixed samples have been stored at 4°C prior to staining, rinse twice with 200 µL HCS Immunofluorescence Buffer before proceeding with staining protocol.
6. Prepare working solution of Mouse Anti-Ki-67 HCS Primary Antibody (6 mL/96-well plate) as follows: Add 60 µL of thawed primary antibody to 5.94 mL of HCS Immunofluorescence Buffer (see Table 1). Mix well. Remove previous Immunofluorescence Buffer rinse. Add 50 µL of primary antibody solution to each well and incubate for 1 hour at RT.
7. Remove primary antibody solution. Rinse three times with 200 µL HCS Immunofluorescence Buffer.
8. Prepare working solution of HCS Secondary Antibody/Hoechst HCS Nuclear Stain (6 mL/96-well plate) as follows: Add 30 µL of thawed secondary antibody and 30 µL of thawed Hoechst HCS Nuclear Stain to 5.94 mL of HCS Immunofluorescence Buffer (see Table 1). Mix well, protecting solution from light. Remove previous HCS Immunofluorescence Buffer rinse. Add 50 µL of HCS Secondary Antibody/Hoechst HCS Nuclear Stain solution and incubate for 1 hour at RT, protected from light.
9. Remove HCS Secondary Antibody/Hoechst HCS Nuclear Stain solution. Rinse twice with 200 µL HCS Immunofluorescence Buffer.
10. Remove previous HCS Immunofluorescence Buffer rinse. Rinse twice with 200 µL of HCS Wash Buffer, leaving second rinse volume in wells.
11. Seal plate and image immediately, or store plate at 4°C protected from light until ready for imaging.

HCS206 Detection Reagent Specifications			
<i>Primary Antibody working solution</i>			
Reagent	Required dilution of initial reagent	Vol. required for 1 well (50 μL)	Vol. required for 1 plate (6 mL) (includes ~25% excess)
Mouse Anti-Ki-67 HCS Primary Antibody	1:100	0.5 μ L	60 μ L
HCS Immunofluorescence Buffer	None	49.5 μ L	5.94 mL (5940 μ L)
<i>Secondary Antibody/Hoechst HCS Nuclear Stain working solution</i>			
Reagent	Required dilution of initial reagent	Vol. required for 1 well (50 μL)	Vol. required for 1 plate (6 mL) (includes ~25% excess)
HCS Secondary Antibody	1:200	0.25 μ L	30 μ L
Hoechst HCS Nuclear Stain	1:200	0.25 μ L	30 μ L
HCS Immunofluorescence Buffer	None	49.5 μ L	5.94 mL (5940 μ L)

Table 1. Detection Reagent Specifications - HCS206 Mouse Anti-Ki-67 Assay

Image Acquisition and Analysis

HCS206 Image Acquisition Guidelines

Detection Reagent	Objective Lens	Excitation Filter Range [peak/bandwidth (nm)]	Emission Filter Range [peak/bandwidth (nm)]
Hoechst HCS Nuclear Stain	10X	360/40	460/40 (or 535/50 if necessary)
HCS Secondary Antibody, Cy3-donkey anti-mouse IgG	10X	535/50	600/50

HCS206 Image Analysis Guidelines

Cell Parameter	Detection	Segmentation/ Measurement	Rationale
Cell Number	Hoechst HCS Nuclear Stain	Nuclear region (460 nm emission channel). Count number of nuclei. DNA content (nuclear intensity) or nuclear area analyses for cell cycle phase are also possible.	Use total cell number to determine percentage of Ki-67-expressing cells (punctate and/or homogeneous).
Ki-67 Expression	HCS Secondary Antibody, Cy3-conjugated	Nuclear region (600 nm emission channel). Measure Cy3 signal co-localizing with nuclear segmentation. Threshold for (+)/(-) cells displaying Cy3 nuclear intensity above/below a user-defined limit. Limits will likely differ for thresholding of cells displaying punctate (G1/S/G2) vs. homogeneous (M) expression. Determine	G0, G1/S/G2 and M phase Ki-67 expression may be modulated as a result of proliferation rate changes, cell cycle arrest, etc.

		parameters such as percentage/number of (+) or (-) cells, etc.	
--	--	--	--

Table 2. Image Acquisition and Analysis Guidelines – HCS206 Mouse Anti-Ki-67 Assay

Sample Results




Figure 2. HCS206 Mouse Anti-Ki-67 Assay reagent stability.

A549 cells were seeded at 18,000 cells/cm² on 96-well plates in growth media and cultured for 48 hours. Samples were fixed and stained under kit conditions, using either fresh buffers and antibody/Hoechst solutions, or buffers and antibody/Hoechst solutions that had been allowed to sit at room temperature (protected from light) for 24 hours prior to staining. Cells were imaged on the GE IN Cell Analyzer 1000 (3.3) at 10X magnification (10 fields/well) and analyzed using the GE IN Cell Analyzer 1000 Workstation (3.4) Multi Target Analysis algorithm. The percentage of cells expressing homogeneous nuclear Ki-67 (M phase) (% Ki67 (+) [Homogeneous]) was determined by counting the number of Hoechst-segmented nuclei thresholded above an empirically-determined Cy3 nuclear intensity. Signal;background ratios for positive (+) and negative (-) cells were calculated by comparing Cy3 intensities in the nucleus and cytoplasm (as defined by a 3 μ m wide perimeter surrounding the nucleus). (+):(-) Cy3 nuclear intensity ratios were calculated as a measure of contrast between homogeneous nuclear Ki-67-expressing and non-expressing cells. Data presented are mean \pm SD; $n = 3$. No statistically significant difference in signal quality was observed between freshly prepared and 24 hour samples.




Figure 3. Immunofluorescence of untreated and cell cycle-arrested A549 and HeLa cells.

A549 or HeLa cells were plated at 18,000 cells/cm² on 96-well plates in growth media and cultured for 48 hours. Cells were treated for the last 4 hours of culture with either paclitaxel (a G2/M phase cell cycle arresting agent) or 0.4% DMSO (negative control). Cell handling, fixation and immunostaining were performed as according to HCS206 assay protocols. Cells were imaged on the GE IN Cell Analyzer 1000 (3.3) at 10X objective magnification. *Left and center panels*: Merged images of staining with Hoechst HCS Nuclear Stain (blue) and Mouse Anti-Ki-67 HCS Primary/Secondary Antibodies (red). Note the increase in the percentage of cells expressing homogeneous nuclear Ki-67 following paclitaxel-induced arrest of cells in M phase. *Right panel*: Monochromatic images of Ki-67 fluorescence overlaid with segmentation and thresholding generated by the GE IN Cell Analyzer 1000 (3.4) Workstation Multi Target Analysis algorithm (inner ring = nuclear segmentation, outer ring = 3 μ m wide nuclear perimeter for cytoplasmic analysis; homogeneous nuclear Ki-67 (-) cells outlined in red, (+) cells outlined in green).




Figure 4. Homogeneous nuclear Ki-67 dose response of A549 and HeLa cells to cell cycle-arresting agents.

A549 or HeLa cells were plated at 18,000 cells/cm² on 96-well plates in growth media and cultured for 48 hours. Cells were treated for the last 4 hours of culture with serial dilutions of either etoposide (*top panel*, S/G2 phase arrest, max. concentration = 100 μ M) or paclitaxel (*bottom panel*, G2/M phase arrest, max. concentration = 1 μ M). Cell handling, fixation and immunostaining were performed as according to HCS206 assay protocols. Cells were imaged on the GE IN Cell Analyzer 1000 (3.3) at 10X (10 fields/well) and analyzed (nuclear segmentation and homogeneous nuclear Ki-67 (+)/(-) intensity thresholding) using the GE IN Cell Analyzer 1000 Workstation (3.4) Multi Target Analysis algorithm. Data presented are mean \pm SEM, $n = 4$.

Troubleshooting

<u>Problem</u>	<u>Potential Explanations/Solutions</u>
Weak Cy3/Hoechst signal	<p>Improper storage or preparation of Primary/Secondary antibody or Nuclear Stain – retry stain with fresh antibody/dye solution.</p> <p>Inadequate primary/secondary antibody or Nuclear Stain concentrations for cell type – titrate dilutions to optimize signal.</p> <p>Signal may diminish in extremely dense cultures – decrease cell seeding concentration or increase primary/secondary antibody or Hoechst concentration.</p> <p>Optimize exposure times and/or fluorescence filters appropriate to fluorophore.</p>
Excessive background	<p>Improper reagent storage or preparation – retry with fresh reagent (antibodies/dyes and/or buffers). Contaminated buffers/solutions may require 0.2µm filter sterilization.</p> <p>Samples may have dried during staining – retry stain on fresh samples.</p> <p>Excessive primary or secondary antibody concentrations for cell type – titrate dilutions to optimize signal.</p> <p>Check for autofluorescence of microplate.</p>
Excessive Cy3/Hoechst signal	<p>Improper preparation of antibody/dye – retry stain with fresh antibody/dye solutions.</p> <p>Inappropriate antibody/dye concentrations for cell type – titrate dilutions to optimize signal.</p> <p>Optimize exposure times and/or fluorescence filters appropriate to fluorophore.</p>
Cell loss	<p>Optimize liquid aspiration/dispensation rate to reduce shear.</p> <p>Consider protein-coating to improve cell adhesion to microplate.</p> <p>Optimize cell seeding concentrations for better cell adhesion.</p>

<p>Poor nuclear segmentation/intensity thresholding during analysis</p>	<p>Effective segmentation parameters can be HCS system/software-dependent. Consider decreasing cell seeding concentrations for difficulty in analysis of dense cultures (separation of multiple nuclei).</p> <p>Cy3 nuclear intensity thresholding may vary between experiments, depending on cell type, exposure time, duration between staining and imaging, etc. – adjust threshold intensity between (+) and (-) cells for each experiment accordingly.</p>
<p>No/low percentage of Ki-67-expressing cells</p>	<p>Percentages of cells expressing Ki-67 homogeneously or in a punctate manner within the nucleus will vary with cell type, doubling time, seeding density, time in culture, passage number, etc. Optimize culture conditions to maximize expression.</p>
<p>No dose response observed/partial response curve</p>	<p>Efficacy of cell cycle arrest control compounds may vary with cell type, cell species, or quality of reagent storage. Use fresh compound, choose alternate maximum/minimum treatment concentrations, or select more appropriate control compounds for cell type of interest.</p> <p>Perform time-course experiments to determine kinetics of compound effects for cell type of interest. Shorter/longer treatment durations may be required.</p>

References

1. Giuliano KA, Haskins JR, Taylor DL. Advances in high content screening for drug discovery. *Assay Drug Dev Technol.* 2003;1:565–577.
2. Giuliano KA, Johnston PA, Gough A, Taylor DL. Systems cell biology based on high-content screening. *Methods Enzymol.* 2006;414:601-619.
3. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol.* 2000;182(3):311-322.
4. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. *J Clin Oncol.* 2005;23(28):7212-7220.
5. Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. *Pathol Oncol Res.* 2006;12(3):143-147.
6. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. *Int J Cancer.* 1983;31(1):13-20.
7. Gasparri F, Mariani M, Sola F, Galvani A. Quantification of the proliferation index of human dermal fibroblast cultures with the ArrayScan high-content screening reader. *J Biomol Screen.* 2004;9(3):232-243.
8. O'Brien P, Haskins JR. In vitro cytotoxicity assessment. *Methods Mol Biol.* 2007;356:415-425.
9. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. *Arch Toxicol.* 2006;80(9):580-604.
10. Gasparri F, Cappella P, Galvani A. Multiparametric cell cycle analysis by automated microscopy. *J Biomol Screen.* 2006;11(6):586-598.
11. Hoffman AF, Garippa RJ. A pharmaceutical company user's perspective on the potential of high content screening in drug discovery. *Methods Mol Biol.* 2007;356:19-31.
12. Stilwell JL, Guan Y, Neve RM, Gray JW. Systems biology in cancer research: genomics to cellomics. *Methods Mol Biol.* 2007;356:353-365.
13. Blake RA. Target validation in drug discovery. *Methods Mol Biol.* 2007;356:367-377.

14. Montecucco A, Biamonti G. Cellular response to etoposide treatment. *Cancer Lett.* 2007;252(1):9-18.
15. Wang T-H, Wang H-S, Soong Y-K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. *Cancer.* 2000;88(11):2619-2628.

Warranty

Millipore Corporation (“Millipore”) warrants its products will meet their applicable published specifications when used in accordance with their applicable instructions for a period of one year from shipment of the products. **MILLIPORE MAKES NO OTHER WARRANTY, EXPRESSED OR IMPLIED. THERE IS NO WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.** The warranty provided herein and the data, specifications and descriptions of Millipore products appearing in Millipore’s published catalogues and product literature may not be altered except by express written agreement signed by an officer of Millipore. Representations, oral or written, which are inconsistent with this warranty or such publications are not authorized and if given, should not be relied upon.

In the event of a breach of the foregoing warranty, Millipore’s sole obligation shall be to repair or replace, at its option, the applicable product or part thereof, provided the customer notifies Millipore promptly of any such breach. If after exercising reasonable efforts, Millipore is unable to repair or replace the product or part, then Millipore shall refund to the Company all monies paid for such applicable Product. **MILLIPORE SHALL NOT BE LIABLE FOR CONSEQUENTIAL, INCIDENTAL, SPECIAL OR ANY OTHER DAMAGES RESULTING FROM ECONOMIC LOSS OR PROPERTY DAMAGE SUSTAINED BY ANY COMPANY CUSTOMER FROM THE USE OF ITS PRODUCTS.**

© Copyright Millipore Corporation 2008 - All rights reserved